Idiopathic interstitial pneumonias Primum movens: Epithelial, endothelial or whatever

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Calabrese, Fiorella ^a   Giacometti, Cinzia ^a   Rea, Federico ^a   Loy, Monica ^a   Valente, Marialuisa ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Fibroblastic foci; Fibroblasts migration; Fibrogenesis; Idiopathic interstitial pneumonia

Indexed keywords

THROMBIN;

BLOOD VESSEL INJURY; BONE MARROW CELL; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS CELL; LUNG FIBROSIS; LUNG PARENCHYMA; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; BIOPSY, NEEDLE; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG DISEASES, INTERSTITIAL; MALE; PROGNOSIS; PULMONARY FIBROSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 31544475465     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (114)

1. Osler W: The Principles and Practice of Medicine. New York, NY: D. Appleton & Co 1892.
2. Hamman L, Rich A: Acute diffuse interstitial fibrosis of the lung. Bull Johns Hopkins Hosp 1944; 74: 177-212.
3. Liebow AA, Carrington CB: The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M, eds. Frontiers of Pulmonary Radiology. New York, NY: Grune & Stratton Inc 1969: 102-41.
4. Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-15.
5. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
6. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of idiopathic interstitial pneumonias: General principles and recommendations. Am J Respir Crit Cure Med 2002; 165: 277-304.
7. British Thoracic Society and Standards of Care Committee: The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults. Thorax 1999;54(Suppl 1): S1-S28.
8. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
9. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-25.
10. Sheppard D: Pulmonary fibrosis: a cellular overreaction or a failure of communication? J Clin Invest 2001; 107: 1501-2.
11. Gauldie J, Kolb M, Sime PJ: A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res 2002; 3: 1-3.
12. Uhal BD, Joshi I, True AL, et al: Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995; 269; 819-28.
13. Kuwano K, Kunitake R, Kawasaki M, et al: P21 Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154: 477-83.
14. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N: Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997; 16: 91-101.
15. Hagimoto N, Kuwano K, Miyazaki H, et al: Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997; 17: 272-8.
16. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, Selman M: Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275: 1192-9.
17. Kuwano K, Miyazaki H, Hagimoto N, et al: The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am J Respir Cell Mol Biol 1999; 20: 53-60.
18. Kuwano K, Hagimoto N, Kawasaki M, et al: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-19.
19. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL: Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP). J Clin Pathol 2001; 54: 132-8.
20. Maeyama T, Kuwano K, Kawasaki M, et al: Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17: 180-9.
21. Hagimoto N, Kuwano K, Inoshima I, et al: TGF-beta1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells J Immunol 2002; 168: 6470-8.
22. Robinson PC, Watters LC, King TE, Mason RJ: Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis 1988; 137: 585-91.
23. McCormack FX, King TE Jr, Bucher BL, et al: Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 152: 751-9.
24. Thomas AQ, Lane K, Phillips J 3rd, et al: Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular non-specific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322-8.
25. Kasper M, Seidel D, Knels L, et al: Early signs of lung fibrosis after in vitro treatment of rat lung slices with CdCl2 and TGF-beta1. Histochem Cell Biol 2004; 121: 131-40.
26. Fujita J, Dobashi N, Ohtsuki Y, et al: Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 1999; 177: 311-19.
27. Dobashi N, Fujita J, Murota M, et al: Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000; 178: 171-9.
28. Dobashi N, Fujita J, Ohtsuki Y, et al: Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 2000; 67: 397-401.
29. Wang R, Ramos C, Joshi I, et al: Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am J Physiol Lung Cell Mol Physiol 1999; 277: L1158-64.
30. Kuwano K, Nakashima N, Inoshima I, et al: Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003; 21: 232-40.
31. Suhara T, Fukuo K, Sugimoto T, et al: Hydrogen peroxide induces up-regulation of Fas in human endothelial cells. J Immunol 1998; 160: 4042-7.
32. Stridh H, Kimland M, Jones DP, Orrenius S, Hampton MB: Cytochrome c release and caspase activation in hydrogen peroxide- and tributyltin-induced apoptosis. FEBS Lett 1998; 429: 351-5.
33. Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V: Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Res Mol Brain Res 1999; 65: 167-75.
34. McDonald JA: Idiopathic pulmonary fibrosis: a paradigm for lung injury and repair. Chest 1991; 99 (suppl. 3): 87-93.
35. Qunn L, Takemura T, Ikushima S, et al: Hyperplastic epithelial foci in honeycomb lesions in idiopathic pulmonary fibrosis. Virchows Arch 2002; 441: 271-8.
36. Zuo F, Kaminski N, Eugui E, et al: Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-7.
37. Panos RJ, Patel R, Bak PM: Intratracheal administration of hepatocyte growth factor/scatter factor stimulates rat alveolar type II cell proliferation in vivo. Am J Respir Cell Mol Biol 1996; 15: 574-81.
38. Rubin JS, Chan AM, Bottaro DP, et al: A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991: 88: 415-19.
39. Ulich TR, Yi ES, Longmuir K, et al: Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest 1994; 93: 1298-306.
40. Shiratori M, Michalopoulos G, Shinozuka H, Singh G, Ogasawara H, Katyal SL: Hepatocyte growth factor stimulates DNA synthesis in alveolar epithelial type II cells in vitro. Am J Respir Cell Mol Biol 1995; 12: 171-80.
41. Sakai T, Satoh K, Matsushima K, et al: Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization. Am J Respir Cell Mol Biol 1997; 16: 388-97.
42. Crestani B, Dehoux M, Hayem G, et al: Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis. Lab Invest 2002; 82: 1015-22.
43. Mori M, Morishita H, Nakamura H, et al: Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol 2004; 30: 459-69.
44. Mori M, Kida H, Morishita H, et al: Microsatellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2001; 24: 398-404.
45. Lappi-Blanco E, Kaarteenaho-Wiik R, Salo S, et al: Laminin-5 gamma2 chain in cryptogenic organizing pneumonia and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 27-33.
46. Chilosi M, Poletti V, Murer B, et al: Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002; 82: 1335-45.
47. Selman M, Ruiz V, Cabrera S, et al: TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279: L562-74.
48. Dunsmore SE, Saarialho-Kere UK, Roby JD, et al: Matrilysin expression and function in airway epithelium. J Clin Invest 1998; 102: 1321-31.
49. Planus E, Galiacy S, Matthay M, et al: Role of collagenase in mediating in vitro alveolar epithelial wound repair. J Cell Sci 1999; 112: 243-52.
50. Lama V, Moore BB, Christensen P, Toews GB, Peters-Golden M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol 2002; 27: 752-8.
51. Petkova DK, Clelland CA, Ronan JE, Lewis S, Knox AJ: Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43: 381-6.
52. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-6.
53. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G: Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995; 152: 2163-9.
54. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q: Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-4.
55. Hubbard R, Venn A, Lewis S, Britton J: Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8.
56. Selman M, Pardo A: Idiopathic pulmonary fibrosis: an epithelial/ fibroblastic cross-talk disorder. Respir Res 2002; 3: 3.
57. Antoniades HN, Bravo MA, Avila RE, et al: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-64.
58. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q: Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341: 1550-4.
59. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G: Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995; 152: 2163-9.
60. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, Takada A: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997; 156: 631-6.
61. Pan LH, Yamauchi K, Uzuki M, et al: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J 2001; 17: 1220-7.
62. Catravas JD, Lazo JS, Dobuler KJ, Mills LR, Gillis CN: Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am Rev Respir Dis 1983; 128: 740-6.
63. Lazo JS, Lynch TJ, McCallister J: Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells. Am Rev Respir Dis 1986; 134: 73-8.
64. Slosman DO, Polla BS, Donath A: 123I-MIBG pulmonary removal: a biochemical marker of minimal lung endothelial cell lesions. Eur J Nucl Med 1990; 16: 633-7.
65. Schwarz MI, Matthay RA, Sahn SA, Stanford RE, Marmorstein BL, Scheinhorn DJ: Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine 1976; 55: 89-104.
66. Hammar SP, Winterbauer RH, Bockus D, Remington F, Sale GE, Meyers JD: Endothelial cell damage and tubuloreticular structures in interstitial lung disease associated with collagen vascular disease and viral pneumonia. Am Rev Respir Dis 1983; 127: 77-84.
67. Kobayashi O: An electron microscopic study of the pulmonary alveolar capillaries in idiopathic interstitial pneumonia and lungs of collagen vascular diseases. Nihon Kyobu Shikkan Gakkai Zasshi 1991; 29: 1007-16.
68. Cohen S: Idiopathic pulmonary hemosiderosis. Am J Med Sci 1999; 317: 67-74.
69. Steen VD, Medsger TA Jr: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
70. Ihn H, Sato S, Fujimoto M, et al: Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000; 119: 203-9.
71. Wusirika R, Ferri C, Marin M, et al: The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003; 120: 596-606.
72. Magro CM, Allen J, Pope-Harman A, et al: The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol 2003; 119: 556-67.
73. Calabrese F, Giacometti C, Valente M, Loy M, Rea F: Interstitial lung disease with cytomegalovirus and parvovirus B19 coinfection. Am J Clin Pathol 2004; 122: 614-15.
74. Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA: Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 1981; 124: 499-503.
75. Hedgpeth MT, Boulwarc DW: Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum 1988; 31: 545-8.
76. Al-Mayouf SM, Al-Eid W, Bahabri S, Al-Mofada S: Interstitial pneumonitis and air leakage in juvenile dermatomyositis. Rheumatology (Oxford) 2001; 40: 588-90.
77. Inoue T, Okamura M, Negoro N, et al: Anti-Ro/SS-A antibody-positive interstitial pneumonitis in a non-lupus patient. Osaka City Med J 1994; 40: 117-20.
78. Friedman AW, Targoff IN, Arnett FC: Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 459-67.
79. Irving WL, Day S, Johnston ID: Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 1993; 148: 1683-4.
80. Stewart JP, Egan JJ, Ross AJ, et al: The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159: 1336-41.
81. Takabatake N, Arao T, Sata M, et al: Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by (123)1-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 2005; 32: 221-8.
82. Slosman DO, Davidson D, Brill AB, Alderson PO: 131I- metaiodobenzylguanidine uptake in the isolated rat lung: a potential marker of endothelial cell function. Eur J Nucl Med 1988; 13: 543-7.
83. Slosman DO, Donath A, Alderson PO: 131I-metaiodobenzylguanidine and 125I-iodoamphetamine. Parameters of lung endothelial cell function and pulmonary vascular area. Eur J Nucl Med 1989; 15: 207-10.
84. Dodge AB, Patton WF, Yoon MU, et al: Organ and species specific differences in cytoskeletal protein profiles of cultured microvascular endothelial cells. Comp Biochem Physiol B 1991; 98: 461-70.
85. Mineau-Hanschke R, Patton WF, Hechtman HB, Shepro D: Immunolocalization of cytokeratin 19 in bovine and human pulmonary microvascular endothelial cells in situ. Camp Biochem Physiol Comp Physiol 1993; 104: 313-19.
86. Turner-Warwick M: Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18: 225-37.
87. Gracey DR, Divertie MB, Brown AL Jr: Alveolar-capillary membrane in idiopathic interstitial pulmonary fibrosis. Electron microscopic study of 14 cases. Am Rev Respir Dis 1968; 98: 16-21.
88. Coalson JJ: The ultrastructure of human fibrosing alveolitis. Virchows Arch 1982; 395: 181-99.
89. Peao MN, Aguas AP, de Sa CM, Grande NR: Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec 1994; 238: 57-67.
90. Keane MP, Arenberg DA, Lynch JP 3rd, et al: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159: 1437-43.
91. Ebina M, Shimizukawa M, Shibata N, et al: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-8.
92. Lappi-Blanco E, Kaarteenaho-Wiik R, Soini Y, Risteli J, Paakko P: Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized. Human Pathol 1999; 30: 1192-6.
93. Peyrol S, Cordier JF, Grimaud JA: Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 1990; 137: 155-70.
94. Lappi-Blanco E, Soini Y, Paakko P; Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999; 1777: 367-76.
95. Renzoni EA, Walsh DA, Salmon M, et al: Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167: 438-43.
96. Lauer G, Sollberg S, Cole M, et al: Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000; 115: 12-18.
97. Cosgrove GP, Brown KK, Schiemann WP, et al: Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-51.
98. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM: ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164: 2239-42.
99. Howell DC, Laurent GJ, Chambers RC: Howell DC Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Bioch Soc Trans 2002; 30: 211-16.
100. Phan SH, Gharaee-Kermani M, Wolber F, Ryan US: Stimulation of rat endothelial cell transforming growth factor-beta production by bleomycin. J Clin Invest 1991; 87: 148-54.
101. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA: Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154-66.
102. Burkhardt A, Cottier H: Cellular events in alveolitis and the evolution of pulmonary fibrosis. Virchows Arch B Cell Pathol 1989; 58: 1-13.
103. Hallgren R, Bjermer L, Lundgren R, Venge P: The eosinophil component of the alveolitis in idiopathic pulmonary fibrosis. Signs of eosinophil activation in the lung are related to impaired lung function. Am Rev Respir Dis 1989; 139: 373-7.
104. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J: The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest 1997; 112: 1338-43.
105. Ozaki T, Hayashi H, Tani K, Ogushi F, Yasuoka S, Ogura T: Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992; 145: 85-91.
106. Noguchi H, Kephart GM, Colby TV, Gleich GJ: Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992; 140: 521-8.
107. Broekelmann TJ, Limper AH, Colby TV, McDonald JA: Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991; 88: 6642-6.
108. Antoniades HN, Bravo MA, Avila RE, et al: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-64.
109. Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL, Rom WN: Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 1597-603.
110. Fortoul TI, Barrios R.: Mast cells and idiopathic lung fibrosis. Arch Invest Med 1990; 21: 5-10.
111. Hunt LW, Colby TV, Weiler DA, Sur S, Butterfield JH: Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin Proc 1992; 67: 941-8.
112. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
113. Dunsmore SE, Shapiro SD: The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J Clin Invest 2004; 113: 180-2.
114. Phillips RJ, Burdick MD, Hong K, et al: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-46.